Understanding the pharmacokinetics of anxiolytic drugs

By Altamura Alfredo Carlo   Moliterno Donatella   Paletta Silvia   Maffini Michele   Mauri Massimo Carlo   Bareggi Silvio  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, Iss. 4, 2013-04 ,pp. : 423-440

Informa Healthcare

Access to resources Recommend Favorite

The GABAA-BZR Complex as Target for the Development of Anxiolytic Drugs

By  

Current Topics in Medicinal Chemistry, Vol. 12, Iss. 4, 2012-02 ,pp. : 254-269

Bentham Science Publishers

Access to resources Recommend Favorite

Neuroendocrine profile of the potential anxiolytic drug S-20499

By Levy A.D.   Li Q.   Gustafson M.   Van de Kar L.D.  

European Journal of Pharmacology, Vol. 274, Iss. 1, 1995-02 ,pp. : 141-149

Elsevier

Access to resources Recommend Favorite

MicroRNA: Potential Targets for the Development of Novel Drugs?

By Wu Wei  

Drugs in R&D, Vol. 10, Iss. 1, 2010-05 ,pp. : 1-8

Adis International

Access to resources Recommend Favorite

An approach to the development of novel antihypertensive drugs: potential role of sodium pump inhibitors

By Goto A.   Yamada K.  

Trends in Pharmacological Sciences, Vol. 19, Iss. 6, 1998-06 ,pp. : 201-204

Elsevier

Access to resources Recommend Favorite